TARDBP and amyotrophic lateral sclerosis: The lack of specificity [60] and sensitivity in detecting circulating TDP‐43 levels in early‐stage ALS or atypical cases [61], that limited its diagnostic value particularly in distinguishing between ALS and other TDP‐43 proteinopathies, have been largely addressed by: (a) recent technological advancements such as single‐molecule array (Simoa) and immunoprecipitation‐mass spectrometry (IP‐MS), which enable enhanced detection and more reliable quantification, and (b) combining more than one biomarker.